Sunday, November 8, 2026

GBP/USD Went Down By Over 2% In The Last 21 Sessions

ViaNews Editorial Team

August 15, 2023

GBP/USD Went Down By Over 2% In The Last 21 Sessions

(VIANEWS) - GBP/USD (GBPUSD) has been up by 2.87% for the last 21 sessions. At 19:07 EST on Tuesday, 15 August, GBP/USD (GBPUSD) is $1.27.

Gbp/usd oscillates in a range below 1.2700 mark, traders keenly await UK jobs data

Nevertheless, the data will determine how many further rate hikes the BoE has left in the tank and provide a fresh directional impetus to the GBP/USD pair., The GBP/USD pair fails to capitalize on the overnight modest bounce from the 100-day Simple Moving Average (SMA), near the 1.2615 area, or its lowest level since late June and oscillates in a narrow range during the Asian session on Tuesday.

Gbp/usd upthrust spurred by uk’s wage growth, despite US retail sales surge

A daily close above those levels could impulse the GBP/USD exchange rate toward the 1.2800 figure, followed by 1.2900 and the July 27 pivot high at 1.2995. , Although the GBP/USD remains in consolidation, it acquired a slight bullish bias, but its advancement is being capped by the 50 and 20-day Exponential Moving Average (EMA), each at 1.2734 and 1.2756, respectively.

GBP/USD's yearly highs and lows, it's 22.362% up from its 52-week low and 3.363% down from its 52-week high.

Volatility

GBP/USD's last week, last month's, and last quarter's current intraday variation average was a negative 0.16%, a negative 0.15%, and a positive 0.36%, respectively.

GBP/USD's highest amplitude of average volatility was 0.23% (last week), 0.35% (last month), and 0.36% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/USD's Forex is considered to be overbought (>=80).

Previous days news about GBP/USD (GBPUSD)

  • Gbp/usd struggles to justify hawkish boe concerns around 1.2700, UK inflation, FOMC minutes in focus. According to FXStreet on Monday, 14 August, "Above all, fears of the British recession gained major attention and joined economic/geopolitical fears from China to underpin the US Treasury bond yields, which in turn exerts downside pressure on the GBP/USD price.", "Although a downside break of an ascending trend line from early March, around 1.2830 at the latest, keeps the GBP/USD bears hopeful, a six-week-old rising support line surrounding 1.2630 restricts immediate declines of the Cable pair."
  • Pound sterling price news and forecast: gbp/usd extends its downside around 1.2665. According to FXStreet on Monday, 14 August, "The GBP/USD pair remains under pressure and trades in a negative territory for the fourth consecutive week. "
  • Gbp/usd price analysis: rebound at two-week lows, as double-bottom suggests potential gains. According to FXStreet on Monday, 14 August, "From a technical perspective, the GBP/USD is neutral-upward biased, as the major dived towards the 100-day Exponential Moving Average (EMA) at 1.2609. ", "GBP/USD aims upward for minimal gains of 0.02% as the Asian session begins, but still printing weekly losses following Monday's session in which the GBP/USD lost 0.10% and reached a two-week low. "

More news about GBP/USD (GBPUSD).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com